Extended-release lamotrigine is used in combination with other anticonvulsant agents in the management of partial seizures, with or without secondary generalization, in adults and children 13 years of ...

DETROIT, Nov. 12 -- Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD) announced today that the US Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated ...

September 6, 2006 — The US Food and Drug Administration (FDA) has approved first-time generic formulations for ciprofloxacin 200-mg/20-mL, 400-mg/40-mL, and 1200-mg/20-mL single-dose vials in the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted approval to Amring Pharmaceuticals Inc. for its generic lamotrigine ODT, according to a ...

Boston, MA, May 1, 2007 -- Data from two clinical trials presented today at the American Academy of Neurology (AAN) meeting suggest that an investigational once daily extended release formulation of ...

Reassurance as to the bioequivalence of generic formulations of the antiepileptic drug lamotrigine with the branded product, Lamictal (GlaxoSmithKline), has come from a new study sponsored by the US ...

Patients with certain types of seizures have a new generic treatment option. The Food and Drug Administration has cleared Zydus Cadila’s lamotrigine extended release tablets in dosage strengths of 25 ...

Combining lamotrigine with quetiapine improves the treatment of depressive symptoms in patients with bipolar disorder, with the benefits maintained for at least a year, show findings from the CEQUEL ...